During a virtual event, Thomas Martin, MD, and participants considered the use of the on-body injector for subcutaneous isatuximab for a frail patient with transplant-ineligible newly diagnosed myeloma.
|Articles|October 28, 2014
- Gastrointestinal Cancers (Issue 3)
- Volume 3
- Issue 1
Unanswered Questions Regarding the Treatment of Pancreatic NETs
Author(s)James C. Yao, MD
James C. Yao, MD, gives an overview of the questions that still remain regarding the treatment of pancreatic neuroendocrine tumors (NETs).
Advertisement
James C. Yao, MD, professor, Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, gives an overview of the questions that still remain regarding the treatment of pancreatic neuroendocrine tumors (NETs).
Read more about the treatment of pancreatic NETs > >
Articles in this issue
almost 12 years ago
Targeted Agents and Combinations Being Studied in Pancreatic NETsalmost 12 years ago
Sequencing Agents for the Treatment of Pancreatic NETsalmost 12 years ago
Research on Epidemiology of GIST Identifies Risk Factorsalmost 12 years ago
Antiangiogenic Strategies for mCRC Need Further Explorationalmost 12 years ago
Coping With Comorbidities in Hepatocellular Canceralmost 12 years ago
Strategies in Surveillance: Hepatocellular Carcinomaabout 12 years ago
Immunotherapy and Viral Therapy for Pancreatic CancerAdvertisement
Related to this article
The investigational chemoimmunotherapy antibody-drug conjugate demonstrated enhanced tumor inhibition in preclinical models.
Updated ARC-20 data show casdatifan delivers durable responses and strong survival in clear cell renal cell carcinoma, alone and in key first-line combinations.
Rural breast cancer deaths rise faster than urban rates, driven by low income, later diagnosis, and treatment gaps—warning of widening disparities by 2035.
The TASKIN trial found a 12-month overall survival rate of 61.3% with vilamakitug plus standard-of-care therapy, with exploratory findings suggesting potential benefit in right-sided tumors.
Lyudmila Bazhenova, MD, discusses the FDA’s expanded approval of taletrectinib for ROS1-positive non–small cell lung cancer.
UGN-103, a formulation of intravesical mitomycin as treatment for low-grade intermediate-risk non–muscle-invasive bladder cancer, will receive FDA review with a PDUFA date of June 14, 2027.
FDA approves dostarlimab for MSI-H/dMMR locally advanced rectal cancer, driving high complete responses and helping many patients avoid surgery, radiation, and chemo.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Dostarlimab Receives FDA Approval for MSI-H/dMMR Locally Advanced Rectal Cancer
2
Dr Bazhenova on the Updated FDA Label for Taletrectinib in ROS1+ NSCLC
3
MC001 Receives FDA Fast Track Designation in Pancreatic Cancer
4
Vilamakitug Meets Phase 2 Efficacy Criterion in Refractory Metastatic Colorectal Cancer
5